Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

A Hayat; S McGuckin; E Conneally; P V Brown; S R McCann; M Lawler; F Quinn; E Delaney; P O'Rourke; S Liptrot; D O'Brien; E Vandenberghe; Mark Lawler

doi:10.1007/s11845-009-0358-9

Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

A Hayat, S McGuckin, E Conneally, P V Brown, S R McCann, M Lawler, F Quinn, E Delaney, P O'Rourke, S Liptrot, D O'Brien, E Vandenberghe, Mark Lawler

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

BACKGROUND: Combined Fludarabine and Cyclophosphamide is now standard first-line therapy in chronic lymphocytic leukaemia (CLL) and the addition of Rituximab improves outcome.

METHODS: We adopted a modified Fludarabine, Cyclophosphamide and Rituximab (FCR) protocol in treating 39 patients (median age 57 years) with progressive or advanced CLL. Depending on CR, treatment was given for four or six cycles.

RESULT: Twenty-six patients were treatment naïve and 13 were pre-treated. Twelve patients had progressive Binet stage A, 16 stage B and 11 stage C disease. The overall response rate (ORR) was 100%, with 75% achieving CR. Neutropenia was the major toxicity in 71/187 (38%) of the cycles. There were five deaths, two from infection and three from progressive disease. Twenty-six of 31 patients have maintained their post-treatment disease status for a median of 17 months (2-41).

CONCLUSION: We conclude that FCR is a feasible, well-tolerated and effective treatment for patients with CLL.

Original language	English
Pages (from-to)	441-6
Number of pages	6
Journal	Irish journal of medical science
Volume	178
Issue number	4
DOIs	https://doi.org/10.1007/s11845-009-0358-9
Publication status	Published - Dec 2009

Keywords

Adult
Aged
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Neutropenia
Remission Induction
Treatment Outcome
Vidarabine

Access to Document

10.1007/s11845-009-0358-9

Cite this

Hayat, A., McGuckin, S., Conneally, E., Brown, P. V., McCann, S. R., Lawler, M., Quinn, F., Delaney, E., O'Rourke, P., Liptrot, S., O'Brien, D., Vandenberghe, E., & Lawler, M. (2009). Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia. Irish journal of medical science, 178(4), 441-6. https://doi.org/10.1007/s11845-009-0358-9

@article{6f31712cbe874982a80e18ae0279ec87,

title = "Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia",

abstract = "BACKGROUND: Combined Fludarabine and Cyclophosphamide is now standard first-line therapy in chronic lymphocytic leukaemia (CLL) and the addition of Rituximab improves outcome.METHODS: We adopted a modified Fludarabine, Cyclophosphamide and Rituximab (FCR) protocol in treating 39 patients (median age 57 years) with progressive or advanced CLL. Depending on CR, treatment was given for four or six cycles.RESULT: Twenty-six patients were treatment na{\"i}ve and 13 were pre-treated. Twelve patients had progressive Binet stage A, 16 stage B and 11 stage C disease. The overall response rate (ORR) was 100%, with 75% achieving CR. Neutropenia was the major toxicity in 71/187 (38%) of the cycles. There were five deaths, two from infection and three from progressive disease. Twenty-six of 31 patients have maintained their post-treatment disease status for a median of 17 months (2-41).CONCLUSION: We conclude that FCR is a feasible, well-tolerated and effective treatment for patients with CLL.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neutropenia, Remission Induction, Treatment Outcome, Vidarabine",

author = "A Hayat and S McGuckin and E Conneally and Brown, {P V} and McCann, {S R} and M Lawler and F Quinn and E Delaney and P O'Rourke and S Liptrot and D O'Brien and E Vandenberghe and Mark Lawler",

year = "2009",

month = dec,

doi = "10.1007/s11845-009-0358-9",

language = "English",

volume = "178",

pages = "441--6",

journal = "Irish journal of medical science",

issn = "0021-1265",

publisher = "Springer-Verlag London Ltd",

number = "4",

}

Hayat, A, McGuckin, S, Conneally, E, Brown, PV, McCann, SR, Lawler, M, Quinn, F, Delaney, E, O'Rourke, P, Liptrot, S, O'Brien, D, Vandenberghe, E & Lawler, M 2009, 'Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia', Irish journal of medical science, vol. 178, no. 4, pp. 441-6. https://doi.org/10.1007/s11845-009-0358-9

TY - JOUR

T1 - Fludarabine, Cyclophosphamide and Rituximab

T2 - an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

AU - Hayat, A

AU - McGuckin, S

AU - Conneally, E

AU - Brown, P V

AU - McCann, S R

AU - Lawler, M

AU - Quinn, F

AU - Delaney, E

AU - O'Rourke, P

AU - Liptrot, S

AU - O'Brien, D

AU - Vandenberghe, E

AU - Lawler, Mark

PY - 2009/12

Y1 - 2009/12

N2 - BACKGROUND: Combined Fludarabine and Cyclophosphamide is now standard first-line therapy in chronic lymphocytic leukaemia (CLL) and the addition of Rituximab improves outcome.METHODS: We adopted a modified Fludarabine, Cyclophosphamide and Rituximab (FCR) protocol in treating 39 patients (median age 57 years) with progressive or advanced CLL. Depending on CR, treatment was given for four or six cycles.RESULT: Twenty-six patients were treatment naïve and 13 were pre-treated. Twelve patients had progressive Binet stage A, 16 stage B and 11 stage C disease. The overall response rate (ORR) was 100%, with 75% achieving CR. Neutropenia was the major toxicity in 71/187 (38%) of the cycles. There were five deaths, two from infection and three from progressive disease. Twenty-six of 31 patients have maintained their post-treatment disease status for a median of 17 months (2-41).CONCLUSION: We conclude that FCR is a feasible, well-tolerated and effective treatment for patients with CLL.

AB - BACKGROUND: Combined Fludarabine and Cyclophosphamide is now standard first-line therapy in chronic lymphocytic leukaemia (CLL) and the addition of Rituximab improves outcome.METHODS: We adopted a modified Fludarabine, Cyclophosphamide and Rituximab (FCR) protocol in treating 39 patients (median age 57 years) with progressive or advanced CLL. Depending on CR, treatment was given for four or six cycles.RESULT: Twenty-six patients were treatment naïve and 13 were pre-treated. Twelve patients had progressive Binet stage A, 16 stage B and 11 stage C disease. The overall response rate (ORR) was 100%, with 75% achieving CR. Neutropenia was the major toxicity in 71/187 (38%) of the cycles. There were five deaths, two from infection and three from progressive disease. Twenty-six of 31 patients have maintained their post-treatment disease status for a median of 17 months (2-41).CONCLUSION: We conclude that FCR is a feasible, well-tolerated and effective treatment for patients with CLL.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cyclophosphamide

KW - Female

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Male

KW - Middle Aged

KW - Neutropenia

KW - Remission Induction

KW - Treatment Outcome

KW - Vidarabine

U2 - 10.1007/s11845-009-0358-9

DO - 10.1007/s11845-009-0358-9

M3 - Article

C2 - 19495836

SN - 0021-1265

VL - 178

SP - 441

EP - 446

JO - Irish journal of medical science

JF - Irish journal of medical science

IS - 4

ER -

Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this